Ge Long Hui·2026-02-11 10:06Core Viewpoint - Ribocure Pharmaceuticals AB, a subsidiary of Ribocure, has entered into an exclusive global licensing agreement with Madrigal Pharmaceuticals for the development of six preclinical siRNA therapies targeting metabolic dysfunction-related fatty liver disease (MASH) [1][2] Group 1: Agreement Details - The agreement grants Madrigal exclusive global rights to utilize Ribocure's RiboGalSTAR™ and siRNA chemical modification platforms for the development, production, and commercialization of several preclinical single-target and dual-target siRNA assets [1] - Ribocure will receive an upfront payment of $60 million, with potential milestone payments totaling up to $4.4 billion, in addition to potential royalties on net sales [1] - The milestone payments are contingent upon the achievement of certain development, regulatory, and commercialization milestones, indicating uncertainty regarding the final amount Ribocure may receive [1] Group 2: Strategic Implications - This collaboration will leverage the company's proven liver-targeting RiboGalSTAR™ platform to develop new therapies for MASH, marking a significant milestone in the company's path to becoming a global leader in innovative siRNA [2] - The partnership aims to accelerate the company's global development and commercialization strategy, addressing unmet medical needs for MASH patients with more targeted and effective therapies [2]